Regulators of G1 cyclin–dependent kinases and cancers

Sherr CJ: D-type cyclins. Trends Biochem Sci 20: 187–190, 1995

Ortega S, Malumbres M, Barbacid M: Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602: 73–87, 2002

Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer zum Buschenfelde KH, Beach D: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269: 1281–1284, 1995

Steeg PS, Zhou Q: Cyclins and breast cancer. Breast CancerRes Treat 52: 17–28, 1998

Hermeking H, Rago C, Schuhmacher M, Li Q, Barrett JF, Obaya AJ, O'Connell BC, Mateyak MK, Tam W, KohlhuberF, Dang CV, Sedivy JM, Eick D, Vogelstein B, Kinzler KW: Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci USA 97: 2229–2234, 2000

Lutz W, Leon J, Eilers M: Contributions of Myc to tumorigenesis. Biochim Biophys Acta 1602: 61–71, 2002

Bouchard C, Dittrich O, Kiermaier A, Dohmann K, Menkel A, Eilers M, Luscher B: Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Mycdependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev 15: 2042–2047, 2001

Lee MH, Yang HY: Negative regulators of cyclindependent kinases and their roles in cancers. Cell Mol Life Sci 58: 1907–1922, 2001

Sugimoto M, Nakamura T, Ohtani N, Hampson L, Hampson IN, Shimamoto A, Furuichi Y, Okumura K, Niwa S, Taya Y, Hara E: Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1). Genes Dev 13: 3027–3033, 1999

Thompson FH, Nelson MA, Trent JM, Guan XY, Liu Y, Yang JM, Emerson J, Adair L, Wymer J, Balfour C, Massey K, Weinstein R, Alberts DS, Taetle R: Amplification of 19q13.1-q13.2 sequences in ovarian cancer. Gband, FISH, and molecularstudies. Cancer Genet Cytogenet 87: 55–62, 1996

Bienz M: The subcellular destinations of APC proteins. Nat Rev Mol Cell Biol 3: 328–338, 2002

Barth AI, Nelson WJ: What can humans learn from flies about adenomatous polyposis coli? Bioessays 24: 771–774, 2002

Tetsu O, McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422–426, 1999

Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R, Ben-Ze'ev A: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 96: 5522–5527, 1999

Cillo C, Cantile M, Faiella A, Boncinelli E: Homeobox genes in normal and malignant cells. J Cell Physiol 88: 161–169, 2001

Hu G, Lee H, Price SM, Shen MM, Abate-Shen C: Msx homeobox genes inhibit differentiation through upregulation of cyclin D1. Development 128: 2373–2384, 2001

Weijzen S, Rizzo P, Braid M, Vaishnav R, Jonkheer SM, Zlobin A, Osborne BA, Gottipati S, Aster JC, Hahn WC, Rudolf M, Siziopikou K, Kast WM, Miele L: Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 8: 979–986, 2002

Ronchini C, Capobianco AJ: Induction of cyclin D1 transcription and CDK2 activity by Notch(ic): implication for cell cycle disruption in transformation by Notch(ic). Mol Cell Biol 21: 5925–5934, 2001

Lai EC: Keeping a good pathway down: Transcriptional repression of Notch pathway target genes by CSL proteins. EMBO Rep 3: 840–845, 2002

Allan AL, Albanese C, Pestell RG, LaMarre J: Activating transcription factor 3 induces DNA synthesis and expression of cyclin D1 in hepatocytes. J Biol Chem 276: 27272–27280, 2001

Beier F, Lee RJ, Taylor AC, Pestell RG, LuValle P: Identification of the cyclin D1 gene as a target of activating transcription factor 2 in chondrocytes. Proc Natl Acad Sci USA 96: 1433–1438, 1999

Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, Price RH, Jr., Pestell RG, Kushner PJ: Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem 277: 24353–24360, 2002

Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M: Cell cycle-dependent variations in c-Jun and JunB phosphorylation: A role in the control of cyclin D1 expression. Embo J 19: 2056–2068, 2000

Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A, Pestell RG: Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 270: 23589–23597, 1995

Watanabe G, Howe A, Lee RJ, Albanese C, Shu IW, Karnezis AN, Zon L, Kyriakis J, Rundell K, Pestell RG: Induction of cyclin D1 by simian virus 40 small tumor antigen. Proc Natl Acad Sci USA 93: 12861–12866, 1996

Filmus J, Robles AI, Shi W, Wong MJ, Colombo LL, Conti CJ: Induction of cyclin D1 overexpression by activated ras. Oncogene 9: 3627–3633, 1994

Joyce D, Bouzahzah B, Fu M, Albanese C, D'Amico M, SteerJ, Klein JU, Lee RJ, Segall JE, Westwick JK, Der CJ, Pestell RG: Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factorkappaB-dependent pathway. J Biol Chem 274: 25245–25249, 1999

Lee RJ, Albanese C, Fu M, D'Amico M, Lin B, Watanabe G, Haines GK, 3rd, Siegel PM, Hung MC, Yarden Y, Horowitz JM, Muller WJ, Pestell RG: Cyclin D1 is required for transformation by activated Neu and is induced through an E2F-dependent signaling pathway. Mol Cell Biol 20: 672–683, 2000

Watanabe G, Albanese C, Lee RJ, Reutens A, Vairo G, Henglein B, Pestell RG: Inhibition of cyclin D1 kinase activity is associated with E2F-mediated inhibition of cyclin D1 promoter activity through E2F and Sp1. Mol Cell Biol 18: 3212–3222, 1998

Welsh CF, Roovers K, Villanueva J, Liu Y, Schwartz MA, Assoian RK: Timing of cyclin D1 expression within G1 phase is controled by Rho. Nat Cell Biol 3: 950–957, 2001

Sherr CJ, Roberts JM: Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9: 1149–1163, 1995

Wang H, Iakova P, Wilde M, Welm A, Goode T, Roesler WJ, Timchenko NA: C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell 8: 817–828, 2001

Wang H, Goode T, Iakova P, Albrecht JH, Timchenko NA: C/EBPalpha triggers proteasome-dependent degradation of cdk4 during growth arrest. Embo J 21: 930–941, 2002

Xia C, Bao Z, Tabassam F, Ma W, Qiu M, Hua S, Liu M: GCIP, a novel human grap2 and cyclin D interacting protein, regulates E2F-mediated transcriptional activity. J Biol Chem 275: 20942–20948, 2000

Pervin S, Singh R, Chaudhuri G: Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): Potential role of cyclin D1. Proc Natl Acad Sci USA 98: 3583–3588, 2001

Miyakawa Y, Matsushime H: Rapid downregulation of cyclin D1 mRNA and protein levels by ultraviolet irradiation in murine macrophage cells. Biochem Biophys Res Commun 284: 71–76, 2001

Barnouin K, Dubuisson ML, Child ES, Fernandez de Mattos S, Glassford J, Medema RH, Mann DJ, Lam EW: H2O2 induces a transient multi-phase cell cycle arrest in mouse fibroblasts through modulating cyclin D and p21Cip1 expression. J Biol Chem 277: 13761–13770, 2002

Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, Albanese C, Sausville EA, Senderowicz AM: Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 59: 4634–4641, 1999

Hulit J, Bash T, Fu M, Galbiati F, Albanese C, Sage DR, Schlegel A, Zhurinsky J, Shtutman M, Ben-Ze'ev A, Lisanti MP, Pestell RG: The cyclin D1 gene is transcriptionally repressed by caveolin-1. J Biol Chem 275: 21203–21209, 2000

Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, TahirSA, Thompson TC: Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 61: 4386–4392, 2001

Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC: Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 4: 1873–1880, 1998

Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y, Fukunaga A, Shichinohe T, Shinohara T, Itoh T, Kondo S, Katoh H: Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 87: 1140–1144, 2002

Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, Hsu SM: Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol 161: 1647–1656, 2002

Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, Itoh T, Okushiba S, Kondo S, Katoh H: Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 94: 929–933, 2002

Yang G, Truong LD, Wheeler TM, Thompson TC: Caveolin-1 expression in clinically confined human prostate cancer: A novel prognostic marker. Cancer Res 59: 5719–5723, 1999

Diehl JA, Zindy F, Sherr CJ: Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 11: 957–972, 1997

Jackson PK, Eldridge AG: The SCF ubiquitin ligase: An extended look. Mol Cell 9: 923–925, 2002

Yu ZK, Gervais JL, Zhang H: Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21(CIP1/ WAF1) and cyclin D proteins. Proc Natl Acad Sci USA 95: 11324–11329, 1998

Diehl JA, Cheng M, Roussel MF, Sherr CJ: Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellularlocalization. Genes Dev 2: 3499–3511, 1998

Geng Y, Eaton EN, Picon M, Roberts JM, Lundberg AS, Gifford A, Sardet C, Weinberg RA: Regulation of cyclin E transcription by E2Fs and retinoblastoma protein. Oncogene 12: 1173–1180, 1996

Masciullo V, Scambia G, Marone M, Giannitelli C, Ferrandina G, Bellacosa A, Benedetti Panici P, Mancuso S: Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas. Int J Cancer 74: 390–395, 1997

Alle KM, Henshall SM, Field AS, Sutherland RL: Cyclin D1 protein is overexpressed in hyperplasia and intraductal carcinoma of the breast. Clin Cancer Res 4: 847–854, 1998

Takano Y, Kato Y, van Diest PJ, Masuda M, Mitomi H, Okayasu I: Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol 156: 585–594, 2000

Leng X, Noble M, Adams PD, Qin J, Harper JW: Reversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4. Mol Cell Biol 22: 2242–2254, 2002

Dawson S, Apcher S, Mee M, Higashitsuji H, BakerR, Uhle S, Dubiel W, Fujita J, MayerRJ: Gankyrin is an ankyrin-repeat oncoprotein that interacts with CDK4 kinase and the S6 ATPase of the 26 S proteasome. J Biol Chem 277: 10893–10902, 2002

Higashitsuji H, Itoh K, Nagao T, Dawson S, Nonoguchi K, Kido T, MayerRJ, Arii S, Fujita J: Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nat Med 6: 96–99, 2000

Fu XY, Wang HY, Tan L, Liu SQ, Cao HF, Wu MC: Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance. World J Gastroenterol 8: 638–643, 2002

Sotillo R, Dubus P, Martin J, de la Cueva E, Ortega S, Malumbres M, Barbacid M: Wide spectrum of tumors in knock-in mice carrying a Cdk4 protein insensitive to INK4 inhibitors. Embo J 20: 6637–6647, 2001

Rane SG, Cosenza SC, Mettus RV, Reddy EP: Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol Cell Biol 22: 644–656, 2002

Bernards R: CDK-independent activities of D type cyclins. Biochim Biophys Acta 1424: M17-M22, 1999

Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ, Bernards R: Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 12: 3488–3498, 1998

Zwijsen RM, Wientjens E, Klompmaker R, van der Sman J, Bernards R, Michalides RJ: CDK-independent activation of estrogen receptor by cyclin D1. Cell 88: 405–415, 1997

Ratineau C, Petry MW, Mutoh H, Leiter AB: Cyclin D1 represses the basic helix-loop-helix transcription factor, BETA2/NeuroD. J Biol Chem 277: 8847–8853, 2002

Hirai H, Sherr CJ: Interaction of D-type cyclins with a novel myb-like transcription factor, DMP1. Mol Cell Biol 16: 6457–6467, 1996

Inoue K, Roussel MF, Sherr CJ: Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci USA 96: 3993–3998, 1999

Inoue K, Wen R, Rehg JE, Adachi M, Cleveland JL, Roussel MF, Sherr CJ: Disruption of the ARF transcriptional activatorDMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes Dev 14: 1797–1809, 2000

Inoue K, Zindy F, Randle DH, Rehg JE, Sherr CJ: Dmp1 is haplo-insufficient fortumorsuppr ession and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev 15: 2934–2939, 2001

Estanyol JM, Jaumot M, Casanovas O, Rodriguez-Vilarrupla A, Agell N, Bachs O: The protein SET regulates the inhibitory effect of p21(Cip1) on cyclin Ecyclin-dependent kinase 2 activity. J Biol Chem 274: 33161–33165, 1999

Bresnahan WA, Albrecht T, Thompson EA: The cyclin E promoter is activated by human cytomegalovirus 86-kDa immediate early protein. J Biol Chem 273: 22075–22082, 1998

Vogt B, Zerfass-Thome K, Schulze A, Botz JW, Zwerschke W, Jansen-Durr P: Regulation of cyclin E gene expression by the human papillomavirus type 16 E7 oncoprotein. J Gen Virol 80: 2103–2113, 1999

Hu W, Bellone CJ, Baldassare JJ: RhoA stimulates p27(Kip) degradation through its regulation of cyclin E/ CDK2 activity. J Biol Chem 274: 3396–3401, 1999

Blomberg I, Hoffmann I: Ectopic expression of Cdc25A accelerates the G(1)/ S transition and leads to premature activation of cyclin E-and cyclin A-dependent kinases. Mol Cell Biol 19: 6183–6194, 1999

DeGregori J, Kowalik T, Nevins JR: Cellular targets for activation by the E2F1 transcription factor include DNA synthesis-and G1/S-regulatory genes. Mol Cell Biol 15: 4215–4224, 1995

Ohtani K, DeGregori J, Nevins JR: Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci USA 92: 12146–12150, 1995

Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, Keyomarsi K: Tumor-specific proteolytic processing of cyclin E generates hyperactive lowermolecular-weight forms. Mol Cell Biol 21: 6254–6269, 2001

Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, KinzlerKW, Vogelstein B: 14–3–3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1: 3–11, 1997

Laronga C, Yang HY, Neal C, Lee MH: Association of the cyclin-dependent kinases and 14–3–3 sigma negatively regulates cell cycle progression. J Biol Chem 275: 23106–23112, 2000

Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B: 14–3–3Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 401: 616–620, 1999

Shintani S, Ohyama H, Zhang X, McBride J, Matsuo K, Tsuji T, Hu MG, Hu G, Kohno Y, Lerman M, Todd R, Wong DT: p12(DOC-1) is a novel cyclin-dependent kinase 2-associated protein. Mol Cell Biol 20: 6300–6307, 2000

Matsuo K, Shintani S, Tsuji T, Nagata E, Lerman M, McBride J, Nakahara Y, Ohyama H, Todd R, Wong DT: p12(DOC-1), a growth suppressor, associates with DNA polymerase alpha/primase. Faseb J 14: 1318–1324, 2000

Zukerberg LR, Patrick GN, Nikolic M, Humbert S, Wu CL, Lanier LM, GertlerFB, Vidal M, Van Etten RA, Tsai LH: Cables links Cdk5 and c-Abl and facilitates Cdk5 tyrosine phosphorylation, kinase upregulation, and neurite outgrowth. Neuron 26: 633–646, 2000

Wu CL, Kirley SD, Xiao H, Chuang Y, Chung DC, Zukerberg LR: Cables enhances cdk2 tyrosine 15 phosphorylation by Wee1, inhibits cell growth, and is lost in many human colon and squamous cancers. Cancer Res 61: 7325–7332, 2001

Yam CH, Ng RW, Siu WY, Lau AW, Poon RY: Regulation of cyclin A-Cdk2 by SCF component Skp1 and F-box protein Skp2. Mol Cell Biol 19: 635–645, 1999

Mongay L, Plaza S, Vigorito E, Serra-Pages C, Vives J: Association of the cell cycle regulatory proteins p45(SKP2) and CksHs1. Functional effect on CDK2 complex formation and kinase activity. J Biol Chem 276: 25030–25036, 2001

Ganoth D, Bornstein G, Ko TK, Larsen B, Tyers M, Pagano M, Hershko A: The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol 3: 321–324, 2001

Carrano AC, Eytan E, Hershko A, Pagano M: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitorp27. Nat Cell Biol 1: 193–199, 1999

Harris TE, Albrecht JH, Nakanishi M, Darlington GJ: CCAAT/enhancer-binding protein-alpha cooperates with p21 to inhibit cyclin-dependent kinase-2 activity and induces growth arrest independent of DNA binding. J Biol Chem 276: 29200–29209, 2001

Truong BT, Lee YJ, Lodie TA, Park DJ, Perrotti D, Watanabe N, KoefflerHP, Nakajima H, Tenen DG, Kogan SC: CCAAT/enhancer binding proteins repress the leukemic phenotype of acute myeloid leukemia. Blood 3: 3, 2002

Ono T, Kitaura H, Ugai H, Murata T, Yokoyama KK, Iguchi-Ariga SM, Ariga H: TOK-1, a novel p21Cip1-binding protein that cooperatively enhances p21-dependent inhibitory activity toward CDK2 kinase. J Biol Chem 275: 31145–31154, 2000

Hall C, Nelson DM, Ye X, Baker K, DeCaprio JA, SeeholzerS, Lipinski M, Adams PD: HIRA, the human homologue of yeast Hir1p and Hir2p, is a novel cyclincdk2 substrate whose expression blocks S-phase progression. Mol Cell Biol 21: 1854–1865, 2001

Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM: Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 10: 1979–1990, 1996

Yeh KH, Kondo T, Zheng J, Tsvetkov LM, Blair J, Zhang H: The F-box protein SKP2 binds to the phosphorylated threonine 380 in cyclin E and regulates ubiquitin-dependent degradation of cyclin E. Biochem Biophys Res Commun 281: 884–890, 2001

Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI: Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413: 316–322, 2001

Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IK: Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 413: 311–316, 2001

Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW, Elledge SJ: Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 294: 173–177, 2001

Spruck CH, Strohmaier H, Sangfelt O, Muller HM, Hubalek M, Muller-Holzner E, Marth C, Widschwendter M, Reed SI: hCDC4 gene mutations in endometrial cancer. Cancer Res 62: 4535–4539, 2002

Dealy MJ, Nguyen KV, Lo J, GstaigerM, Krek W, Elson D, Arbeit J, Kipreos ET, Johnson RS: Loss of Cul1 results in early embryonic lethality and dysregulation of cyclin E. Nat Genet 23: 245–248, 1999

Singer JD, Gurian-West M, Clurman B, Roberts JM: Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells. Genes Dev 13: 2375–2387, 1999

Marone M, Scambia G, Giannitelli C, Ferrandina G, Masciullo V, Bellacosa A, Benedetti-Panici P, Mancuso S: Analysis of cyclin E and CDK2 in ovarian cancer: Gene amplification and RNA overexpression. Int J Cancer 75: 34–39, 1998

Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM: Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancerpatients. Nat Med 3: 222–225, 1997

Mishina T, Dosaka-Akita H, Hommura F, Nishi M, Kojima T, Ogura S, Shimizu M, Katoh H, Kawakami Y: Cyclin E expression, a potential prognostic marker for non-small cell lung cancers. Clin Cancer Res 6: 11–16, 2000

Fukuse T, Hirata T, Naiki H, Hitomi S, Wada H: Prognostic significance of cyclin E overexpression in resected non-small cell lung cancer. Cancer Res 60: 242–244, 2000

Spruck CH, Won KA, Reed SI: Deregulated cyclin E induces chromosome instability. Nature 401: 297–300, 1999

Hinchcliffe EH, Sluder G: Centrosome duplication: Three kinases come up a winner! Curr Biol 11: R698-R701, 2001

Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, Knudsen ES, Hofmann IA, Snyder JD, Bove KE, Fukasawa K: Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 103: 127–140, 2000

Hinchcliffe EH, Li C, Thompson EA, Maller JL, Sluder G: Requirement of Cdk2-cyclin E activity for repeated centrosome reproduction in Xenopus egg extracts. Science 283: 851–854, 1999

Dhillon NK, Mudryj M: Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest. Oncogene 21: 4626–4634, 2002

Davis ST, Benson BG, Bramson HN, Chapman DE, Dickerson SH, Dold KM, Eberwein DJ, Edelstein M, Frye SV, Gampe Jr RT, Griffin RJ, Harris PA, Hassell AM, Holmes WD, HunterRN, Knick VB, Lackey K, Lovejoy B, Luzzio MJ, Murray D, Parker P, Rocque WJ, Shewchuk L, Veal JM, WalkerDH, KuyperLF: Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 291: 134–137, 2001

Ma T, Van Tine BA, Wei Y, Garrett MD, Nelson D, Adams PD, Wang J, Qin J, Chow LT, Harper JW: Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev 14: 2298–2313, 2000

Zhao J, Kennedy BK, Lawrence BD, Barbie DA, Matera AG, FletcherJA, Harlow E: NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. Genes Dev 14: 2283–2297, 2000

Zhao J, Dynlacht B, Imai T, Hori T, Harlow E: Expression of NPAT, a novel substrate of cyclin ECDK2, promotes S-phase entry. Genes Dev 12: 456–461, 1998

Fry DW, Bedford DC, Harvey PH, Fritsch A, Keller PR, Wu Z, Dobrusin E, Leopold WR, Fattaey A, Garrett MD: Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J Biol Chem 276: 16617–16623, 2001

Soni R, O'Reilly T, Furet P, Muller L, Stephan C, Zumstein-Mecker S, Fretz H, Fabbro D, Chaudhuri B: Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J Natl Cancer Inst 93: 436–446, 2001

Toogood PL: Cyclin-dependent kinase inhibitors for treating cancer. Med Res Rev 21: 487–498, 2001

Almond JB, Cohen GM: The proteasome: A novel target forcancer chemotherapy. Leukemia 16: 433–443, 2002